ロード中...

Population Pharmacokinetic Modeling of Secukinumab in Patients With Moderate to Severe Psoriasis

Secukinumab is a human monoclonal antibody with demonstrated efficacy for moderate to severe psoriasis; it binds to and neutralizes interleukin (IL)‐17A. The pharmacokinetic (PK) parameters of secukinumab were best described by a 2‐compartment model. Only weight was included in the final model, as o...

詳細記述

保存先:
書誌詳細
出版年:J Clin Pharmacol
主要な著者: Bruin, Gerard, Loesche, Christian, Nyirady, Judit, Sander, Oliver
フォーマット: Artigo
言語:Inglês
出版事項: John Wiley and Sons Inc. 2017
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5485066/
https://ncbi.nlm.nih.gov/pubmed/28273356
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.876
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!